These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28841513)

  • 1. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
    Krapf MK; Gallus J; Wiese M
    Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
    Juvale K; Gallus J; Wiese M
    Bioorg Med Chem; 2013 Dec; 21(24):7858-73. PubMed ID: 24184213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
    Krapf MK; Wiese M
    J Med Chem; 2016 Jun; 59(11):5449-61. PubMed ID: 27148793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
    Krapf MK; Gallus J; Spindler A; Wiese M
    Eur J Med Chem; 2019 Jan; 161():506-525. PubMed ID: 30390439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
    Kraege S; Stefan K; Juvale K; Ross T; Willmes T; Wiese M
    Eur J Med Chem; 2016 Jul; 117():212-29. PubMed ID: 27100033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
    Krapf MK; Gallus J; Namasivayam V; Wiese M
    J Med Chem; 2018 Sep; 61(17):7952-7976. PubMed ID: 30075623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors.
    Köhler SC; Vahdati S; Scholz MS; Wiese M
    Eur J Med Chem; 2018 Feb; 146():483-500. PubMed ID: 29407974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).
    Krapf MK; Gallus J; Wiese M
    J Med Chem; 2017 May; 60(10):4474-4495. PubMed ID: 28471656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
    Spindler A; Stefan K; Wiese M
    J Med Chem; 2016 Jul; 59(13):6121-35. PubMed ID: 27280693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2.
    Murakami M; Ohnuma S; Fukuda M; Chufan EE; Kudoh K; Kanehara K; Sugisawa N; Ishida M; Naitoh T; Shibata H; Iwabuchi Y; Ambudkar SV; Unno M
    Drug Metab Dispos; 2017 Nov; 45(11):1166-1177. PubMed ID: 28904007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.
    Silbermann K; Li J; Namasivayam V; Stefan SM; Wiese M
    Eur J Med Chem; 2021 Feb; 212():113045. PubMed ID: 33454462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.
    Valdameri G; Pereira Rangel L; Spatafora C; Guitton J; Gauthier C; Arnaud O; Ferreira-Pereira A; Falson P; Winnischofer SM; Rocha ME; Tringali C; Di Pietro A
    ACS Chem Biol; 2012 Feb; 7(2):322-30. PubMed ID: 22039929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.
    Gozzi GJ; Bouaziz Z; Winter E; Daflon-Yunes N; Honorat M; Guragossian N; Marminon C; Valdameri G; Bollacke A; Guillon J; Pinaud N; Marchivie M; Cadena SM; Jose J; Le Borgne M; Di Pietro A
    Drug Des Devel Ther; 2015; 9():3481-95. PubMed ID: 26170632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grid-independent Descriptors (GRIND) Analysis and SAR Guided Molecular Docking Studies to Probe Selectivity Profiles of Inhibitors of Multidrug Resistance Transporters ABCB1 and ABCG2.
    Shafi T; Jabeen I
    Curr Cancer Drug Targets; 2017; 17(2):177-190. PubMed ID: 27585695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors.
    Gujarati NA; Zeng L; Gupta P; Chen ZS; Korlipara VL
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4698-4704. PubMed ID: 28916341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates.
    Kraege S; Stefan K; Köhler SC; Wiese M
    ChemMedChem; 2016 Nov; 11(22):2547-2558. PubMed ID: 27785905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
    Juvale K; Stefan K; Wiese M
    Eur J Med Chem; 2013 Sep; 67():115-26. PubMed ID: 23851114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.
    Pires ADRA; Lecerf-Schmidt F; Guragossian N; Pazinato J; Gozzi GJ; Winter E; Valdameri G; Veale A; Boumendjel A; Di Pietro A; Pérès B
    Eur J Med Chem; 2016 Oct; 122():291-301. PubMed ID: 27376492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
    Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
    Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.